Deals
Pfizer Said to Hire JPMorgan to Weigh $2 Billion Portfolio Sale
- Firm may sell drugs in cardiology, urology, primary care
- Sale could attract both drugmakers and private equity firms
This article is for subscribers only.
Pfizer Inc. is exploring a sale of a group of treatments in cardiology, urology and primary care as the U.S. drugmaker looks for ways to raise cash and streamline its portfolio, according to people familiar with the matter.
The drugs generate sales of more than $700 million and could fetch more than $2 billion from a buyer, the people said, asking not to be identified because the deliberations are private. Pfizer is working with financial advisers at JPMorgan Chase & Co. on the process, which is at a preliminary stage, the people said.